71 results about "Chronic hepatic" patented technology

The invention belongs to the field of pharmaceutical chemical engineering, and discloses a L-ornithine lipoic acid compound salt, and a preparation method and application thereof. A structural formula of the L-ornithine lipoic acid compound salt is as shown in the formula I. The L-ornithine lipoic acid compound salt has functions of preventing and treating hepatic coma caused by acute and chronic hepatic diseases such as liver cirrhosis, fatty liver, hepatitis and the like and can be used for preparing a medicament for treating hepatic coma. The preparation method for the L-ornithine lipoic acid compound salt is simple and easy to operate and is low in cost; the product is high in purity.

The invention relates to a compound amino acid capsule (8-11) and a preparation method thereof, specifically to a capsule including pellets of eight amino acids and eleven vitamins and a preparation method thereof. The capsule comprises 7 spherical pellets which are composed of the following raw materials by weight: 2.66 to 9.9 parts of a thiamine mononitrate pellet, 16.35 to 20.5 parts of a vitamin pellet a, 35.0 to 44.1 parts of an amino acid pellet a, 11.4 to 14.4 parts of a vitamin pellet b, 6.65 to 10.5 parts of an amino acid pellet b, 12. 73 to 16.0 parts of a vitamin C pellet and 5.7 to 9.36 parts of a vitamin AD bead. The capsule provided by the invention has the advantages of a scientific and reasonable ratio, good stability, no toxic and side effects, high security and good biological effects and can be applied in preparation of medicines used for treating chronic liver and kidney diseases and of foodstuffs used for alleviating and eliminating physical fatigue caused by exercise training. The capsule provided by the invention has characteristics superior to those of the prior art.

The present invention relates to a high-concentration-type water soluble vitamin used for intravenous injections, with each bottle containing 6.2 +-1.6 mg aneurine mononitrate, 9.8+-2.5 mg lactoflavin sodium phosphate, 80+-20 mg nicotinic amide, 9.8+-2.5 mg phosphopyridoxamine, 33.0+-8.3 mg panthoject, 200+-50 mg vitamin, 120 +-30 mu g biotin, 0.8+-0.2 mg acidum folicum, 10.0+-2.5 mu g vitamin B12 and 1-6ml water for injection. The preparing method is as follows: stirring the components mentioned above with water for injection until they are entirety dissolved, freezing-drying them in a freezing-drying machine, pressing them to prepare the water soluble vitamins used for intravenous injection. The water soluble vitamins used for intravenous injection in accordance with the present invention can be used for guarding against and curing cacotrophia caused by deficiency of water soluble vitamins and for auxiliary cure of chronic diseases such as chronic hepatic disease and the like; the water soluble vitamins used for intravenous injection possesses advantages of rapid vitamin supplying, medicament curative effect enhancement, reduced side-effects and the like, can satisfy clinical require for supplying of serious water soluble vitamins deficiency caused by diseases.

The invention relates to a rhodiola rosea and a rhodioside application for inducing stem cells to directionally differentiate into hepatocytes, in particular to a compound inducer of the rhodioside and cell growth factor FGF-4 used for inducing mesenchymal stem cells to directionally differentiate into hepatocytes. The rhodiola rosea develops the new application of rhodiola, which induces mesenchymal stem cells and other stem cells to directionally differentiate into hepatocytes in vitro, and provides the effect of the rhodiola rosea and the rhodioside on inducing the adult stem cells to directionally differentiate into hepatocytes, which is beneficial to further research of the in vivo stem cells transplantation for treating acute or chronic hepatic injury and middle-advanced liver disease field, and provides the basic for new drug development.

The present invention relates to belongs to the field of Chinese medicine technology, relates to compound Chinese medicine preparation for treating chronic hepatosis, and is especially compound Chinese medicine preparation for treating hepatitis and hepatic fibrosis and its preparation process. The compound Chinese medicine preparation is prepared with red sage, fermented aweto powder, peach kernel, pine pollen, gynostemma pentaphylla, schisandra extract and medicinal supplementary material, and may be in different orally taken preparation forms. The compound Chinese medicine preparation has high effect of preventing and treating hepatic fibrosis and treating hepatitis and no obvious toxic side effect.

The invention belongs to the field of biotechnology, and relates to an experimental animal model for transforming nonalcoholic steatohepatitis into liver cancer. In particular, a large and mouse model of nonalcoholic chronic steatohepatitis (NASH) and chronic steatohepatitis developing into chronic liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can be used for chronic fatty Liver, steatohepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, metabolic diseases, diabetes, in vivo experiments of related mechanisms of diabetic complications, new drug development, and non-alcoholic steatohepatitis (NASH), liver It has extremely high application value in the study of the pathogenesis of fibrosis and liver cancer and in drug development.

A preparation method of chronic hepatic injury complicated with stress depression rat model comprises selecting male Wistar rat (body weight of 180-220 g), acclimating for one week, performing open field test ethology screening, and selecting rat having close integration; normally drinking and eating for the first week to the fourth week, and performing hypodermic injection of 40% CCL4 1ml/kg (twice per week); normally drinking and eating from the fifth to the twelfth week, performing hypodermic injection of 40% CCL4 1ml/kg (twice per week), and performing gastric perfusion of normal saline (one time per day); normally drinking and eating in the thirteenth week, and performing gastric perfusion of normal saline (one time per day); performing open field test in the fourteenth to sixteenth week (one rat per cage), normally drinking and eating, performing gastric perfusion of normal saline (one time per day), and offering chronic stress stimulation; and weighing in 112th day, and performing sweet water consumption and open field test. The preparation method provides reference for modeling research of chronic hepatic injury complicated with stress depression, provides effective experiment base for clinical diagnosis of hepatopathy complicated with depression, and provides experimental verification means for the research of drug for treating the hepatopathy complicated with depression.

The invention discloses a pharmaceutical composition for treating or preventing acute and chronic hepatic disease, which is prepared from Chinese medicinal herbs including Bupleurum root, licorice root, root of red rooted saliva, notoginseng, schisandra fruit, curcuma longa, picrorhiza rhizome, cow-bezoar, Chinese angelica root, herba patriniae, astragalus root and alisol. The invention also provides the method for preparation and use of the pharmaceutical composition.

The invention discloses a chronic non-alcoholic steatohepatitis (NASH) non-human primate model, a method for building the same and application of the chronic non-alcoholic steatohepatitis non-human primate model. The chronic non-alcoholic steatohepatitis non-human primate model, the method and the application have the advantages that the chronic non-alcoholic steatohepatitis non-human primate model built by the aid of the method further can be accompanied by pathological characteristics of chronic hepatic fibrosis and hepatic cirrhosis, can be used for research and development of medicines forpreventing or treating chronic non-alcoholic steatohepatitis, the chronic hepatic fibrosis and the hepatic cirrhosis and can be used as an animal model for research on chronic fatty livers, steatohepatitis, the hepatic fibrosis, the hepatic cirrhosis, hepatocellular carcinoma, metabolic diseases, diabetes mellitus and diabetes complications, and accordingly the chronic non-alcoholic steatohepatitis non-human primate model and the method have extremely high application values.

The present invention relates to the field of biotechnology and in particular to a construction method of an experimental animal model, specifically a mouse model, with non-alcoholic steatohepatitis (NASH) transforming into hepatic carcinoma (HCC), and use thereof. The present invention provides a construction method of a mouse model with NASH and chronic steatohepatitis developing into chronic hepatic fibrosis, cirrhosis and HCC. The construction method comprises the following steps: newborn C57BL/6 mice (including male and female newborn mice) are subjected to subcutaneous single injection of streptozotocin (STZ) (100-400 [mu]g/newborn mouse) and the mice begin to be fed with experiment use high-fat feed after the completion of female mouse breastfeeding to construct the NASH mouse model with hepatic fibrosis, cirrhosis and HCC. The provided mouse model is relatively simple in construction process, relatively simple in technical means, and low in construction cost, has an extremely high value as the needed animal model in scientific research and drug research and development, and belongs to a domestic initiative.

The present invention relates to new methods for assessing the risk of a patient, in particular with chronic liver disease, to develop primary liver cancer over time, using functions combining blood biochemical markers.

The invention relates to the technical field of biology and discloses a non-alcoholic chronic fatty liver hepatitis (NASH) rat model and an establishment method and application thereof. An adult rat is fed with special feed (MCD feed) short of methionine and choline or a special high-fat feed (CDAA feed) short of choline, a certain amount of sodium nitrite solution is provided for the animal within a certain time, and the established non-alcoholic chronic fatty liver hepatitis rat model has the characteristics of chronic liver fibrosis and earlier liver fibrosis. The rat model is simple in establishment process, a technical means is easy, the establishment cost is low, the rat model has very high animal model value for scientific research and research and development of drugs, especially serves as a specific animal model with NASH accompanied with severe liver hepatitis and earlier liver fibrosis and belongs to a national initiative.

The invention relates to a medicine with icaritin as the active component for treating hepatic injuries. The pharmacological experiment shows that the icaritin has antiapoptotic, antioxidant and antiphlogistic activities and protective effects on hepatic injuries; and has evident inhibiting effects on the release of active oxygen, cell apoptosis factor and inflammatory cell factor caused by acute and chronic hepatic injury, anoxic hepatic injury and ischemia-reperfusion hepatic injury. The acute toxicity test of the icaritin on a mouse shows that the icaritin has no toxicity. Therefore, the icaritin has wide development prospect, and can be used for preparing new drugs for preventing and treating the acute and chronic hepatic injury, the anoxic hepatic injury and the ischemia-reperfusion hepatic injury.

The invention belongs to the chemical medicine technical field, and particularly relates to a bifendate derivative containing halogen substituent, a preparation method and an application of the bifendate derivative for treating autoimmune disease. AA structure of the bifendate derivative containing halogen substituent is shown as a formula I, the experiments prove that the bifendate derivative containing halogen substituent shown in the formula I has good effect for treating autoimmune disease, and the bifendate derivative containing halogen substituent has the effect for inhibiting autoimmune diseases such as acute hepatitis, chronic hepatic fibrosis or pulmonary fibrosis, and provides a new selection for medicament exploitation for treating diseases.

The invention discloses a non-invasive diagnostic marker for liver cirrhosis related to chronic drug-induced liver injury and application of the non-invasive diagnostic marker. Every two of the five discovered metabolites are combined to construct a peak area ratio or absolute quantification of the peak areas of the metabolites, so that the five discovered metabolites can be used for distinguishing a chronic DILI liver cirrhosis group from a non-liver cirrhosis chronic DILI group. At present, liver puncture pathological examination is a gold standard for liver cirrhosis diagnosis, but the liver puncture pathological examination is related to patient compliance and patient contraindications, and sometimes is difficult to implement; and due to invasive examination, the method is difficult tobe used as a dynamic monitoring and early diagnosis method of the LC-DILI. The non-invasive diagnostic marker and the application thereof provided by the invention can replace common invasive liver puncture pathological examination at present, and have more stable clinical application value.

The invention develops an anti-HBV drug, i.e., a hepatitis B granule, according to folk experience about treatment of hepatitis and the theory of traditional Chinese medicine. The hepatitis B granule is formed by combination of a plurality of Chinese herbal medicines consisting of glossy privet fruit, eclipta herba, spatholobus stem, Chinese thorowax root, red sage root, canton love-pea vine, Japanese climbing fern spore, common selfheal fruit-spike, virgate wormwood herb, European verbena herb and the like. The objective of the invention is to develop a novel natural medicinal preparation for treatment of hepatitis B. According to long-term considerable research of the inventor, the hepatitis B granule and drug serum thereof can inhibit propagation of hepatic HSC-T6 and collagen synthesis and exert obvious protection effects on acute chemical liver injury of mice caused by carbon tetrachloride, paracetamol, D-galactosamine and the like, immunological liver injury caused by concanavalin A and chronic hepatic fibrosis of rats. The hepatitis B granule provided by the invention may possibly become a novel liver protecting drug for patients with acute liver injury and chronic hepatic fibrosis. According to the invention, Guangxi characteristic crude drug resources are dug and systemized, and the novel natural medicinal preparation is provided for treatment of acute liver injury and chronic hepatic fibrosis.

The invention pertains to the technical field of medicine, relating to new compounds which have hepatoprotective activity or stereoisomer and salt thereof, the preparation methods of the compounds or the stereoisomer thereof, medical compositions which comprise the compounds or the stereoisomer and salt thereof as necessary active ingredients, and the application of the compounds or the stereoisomer and salt thereof in the preparation of medicine to cure and/or prevent hepatopathy and inflammatorydisease. The compounds or the stereoisomer and salt thereof of the invention have prominent functions of resisting acute and chronic hepatic injury and good function of antivirus at the same time, as well as prominent anti-inflammatory activity.

The invention relates to application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis. In vitro cell models prove that the methyl ferulic acid has a remarkable inhibition effect on proliferation and collagen synthesis of rat primary hepatic stellate cells (HSC). Animal tests prove that the methyl ferulic acid has a protecting effect on acute hepatic damage caused by carbon tetrachloride (CCl4) and D-galactosamine (D-Gal) of mice and can prevent the hepatic fibrosis. Rat models of chemical hepatic fibrosis caused by CCL4 and rat models of immunity hepatic fibrosis caused by bovine serum albumin prove that the methyl ferulic acid has a good therapeutic action on chronic hepatic fibrosis and can be used for preparing the medicine for preventing and curing the hepatic fibrosis alone or in compound mode.

The invention specifically relates to a levocarnitine sesquihydrate, which belongs to the technical field of medicines. The levocarnitine sesquihydrate obtained in the invention contains one and a half crystal water and has the advantages of a high purity and good stability, having non-obvious moisture absorption and weight gain even under the condition of high humidity. The invention also relates to application of the levocarnitine sesquihydrate in preventing and mitigating myocardial damage, in mitigating and alleviating symptoms of chest pain, in treating coronary heart disease, angina pectoris, heart failure, myocardial infarction and cerebral infarction, in auxiliary treatment of renal disease, chronic pulmonary heart disease, male sterility, acquired immune deficiency syndrome, intermittent claudication, as well as acute and chronic hepatitis, cirrhosis, chronic hepatic insufficiency, muscular atrophy, diabetes and bad postpartum uterus contraction, etc.

The present invention relates to a drug potassium entecavir for treating liver disease, which has the following molecular structure, in which n is crystallization water number containing in potassium entecavir, Value range of n being 0-6. The present invention also provides a preparation method of potassium entecavir characterized as carrying out acid and alkaline reaction of entecavir and alkaline compound containing potassium, then adding precipitator for elution, filtering, drying, then potassium entecavir being obtained. The inventive potassium entecavir has merits of high stability, good dissolution, good curative effect and being convenient for clinic use.